Tracers / [131I]I-GMIB-4AH29
[131I]I-GMIB-4AH29
Also written as [I-131]I-GMIB-4AH29
- Radionuclide
- I-131 t½ 11549 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 2
What it is
- Compound class
- single-domain antibody (sdAb)
- Target / mechanism
- —
- Clinical application
- —
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | SPE | — | >99.7% | SGMTB-Boc2 | 41390415 2025 J Transl Med N-succinimidyl 4-(1,2-bis-tert-butoxycarbonyl)guanidinomethyl-3-(trimethylstannyl)benzoate precursor (SGMTB- Boc2; 50–500 µg) dissolved in anhydrous acetonitrile (0.2-1 mL) was incubated for 10 min at RT with Na[131I]I |
| — | — | — | — | — | 4AH29 | 42364406 2026 Nucl Med Biol |
Need this precursor?We can point you to suppliers for [131I]I-GMIB-4AH29, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 3 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.